Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Patients Remaining Obese After Metabolic Surgery
NCT07163650Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of efsubaglutide alfa in obesity, sponsored by Nanjing Drum-Tower Hospital. Started Sep 2025; status: recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07163650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163650.